Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
PD-1/PD-L1 immune checkpoint inhibitors
autoimmune disease (AID)
autoimmune hepatitis (AIH)
autoimmune liver diseases (AILD)
immune checkpoint inhibitors (ICI)
immune related adverse effects (irAEs)
primary biliary cholangitis (PBC)
primary sclerosing cholangites (PSC)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
12
01
2024
accepted:
15
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
epublish
Résumé
[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].
Identifiants
pubmed: 38327519
doi: 10.3389/fimmu.2024.1369747
pmc: PMC10848160
doi:
Types de publication
Published Erratum
Langues
eng
Sous-ensembles de citation
IM
Pagination
1369747Commentaires et corrections
Type : ErratumFor
Informations de copyright
Copyright © 2024 Kocheise, Piseddu, Vonderlin, Tjwa, Buescher, Meunier, Goeggelmann, Fianchi, Dumortier, Barciela, Gevers, Beretta-Piccoli, Londoño, Frankova, Roesner, Joerg, Schmidt, Glaser, Sutter, Fründt, Lohse, Huber, von Felden, Sebode and Schulze.